

**Agenda Item 14: Item 14h(i)**

**Meeting:** Buckinghamshire, Oxfordshire, and Berkshire West CCGs (BOB) Governing Bodies Meeting in Common (in public)

<b>Date of Meeting</b>	10 June 2021
<b>Title of Paper</b>	OCCG Finance Committee minutes, 21 <sup>st</sup> January, and 18 <sup>th</sup> March 2021
<b>Lead Director</b>	Gareth Kenworthy, Director of Finance
<b>Author(s)</b>	Duncan Smith, Lay Member and Finance Committee Chair
<b>Paper Type</b>	Indicate whether the report presented is for: Information
<b>Action Required</b>	The detailed work of the Finance Committee provides further assurance to the Board that OCCG is managing its finances effectively and in accordance with the financial plans and budgets approved by this Board. Board members are asked to consider if they are receiving enough information in the Board's finance report and through the minutes of Committee meetings to assure themselves in relation to OCCG's financial performance.

**Executive Summary**

The Committee draws to the attention of Board members, the following:

**21<sup>st</sup> January 2021**

- Monthly Finance Report – The overall position at Month 9 remains on plan, with a deficit of £4.5m for Months 7–12. Due to a lag in reimbursement of costs, OCCG is currently reporting a deficit forecast outturn on 31<sup>st</sup> March 2021. There is sustained pressure within the prescribing budget, assessed at c£1.0m. The Committee has requested a more detailed report to review the drivers for the overspending on this budget.
- Delegated budgets - There is an issue identified that funding is not keeping pace with the population growth in Oxfordshire. The gap is estimated to be c.£2-3.0m. This has been raised with NHSE.

**18<sup>th</sup> March 2021**

- Monthly Finance Report – A small year to date deficit at M11 will move to a £0.5m surplus on 31<sup>st</sup> March 2021.
- Prescribing Budget – The Committee reviewed the drivers of the pressures on this budget and potential mitigations. The drivers were: increase in GP

prescribing in December 2020; Category M drug price increases; No Cheaper Stock Obtainable (NCSO) price concessions; former NCSO drugs prices recalculations within the Drug Tariff; and continued growth of more expensive Direct Oral Anti-Coagulant (DOACs) prescribing. The total costs of the pressures at Month 9 were c£3.4m. The Committee

- Financial Planning for 2021/22 - It is anticipated that the current financial regime will be rolled forward for six months, before there is a return to a 'business as usual' finance regime.
- Joint Commissioning – The Committee reviewed and made comments on the proposed governance and management arrangements for the proposed Health, Education and Social Care Joint Commissioning Executive. The Committee agreed to extend the existing Section 75 Agreement until the new arrangements had been agreed and requested that the Section 75 Financial Performance Dashboard Reporting be retained.